Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atezolizumab + bevacizumab + camonsertib
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This drug is a combination therapy consisting of three agents for cancer treatment: atezolizumab (an immune checkpoint inhibitor), bevacizumab (a vascular endothelial growth factor [VEGF] inhibitor), and camonsertib (an ATR inhibitor, a small molecule targeting DNA repair mechanisms). - **Atezolizumab** is a humanized monoclonal antibody that inhibits PD-L1, thereby unleashing the immune system against tumor cells. - **Bevacizumab** is a monoclonal antibody that binds VEGF-A, inhibiting angiogenesis and tumor vascularization. - **Camonsertib** is a small molecule inhibitor of ataxia-telangiectasia and Rad3-related kinase (ATR), which impairs DNA damage response in cancer cells and may sensitize them to immunotherapy and anti-angiogenic therapy. This triple combination is under investigation for multiple solid tumors, with clinical trials focusing on advanced or metastatic malignancies, especially those with dysfunctional DNA repair pathways[8][10].
- Other names
- atezolizumab + bevacizumab + camonsertib
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on atezolizumab + bevacizumab + camonsertib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atezolizumab + bevacizumab + camonsertib.